lt p gt Neurotrope BioScience, Inc. is a specialty biopharmaceutical company developing new therapeutics for the treatment of rare diseases Orphan diseases and Alzheimers Disease. NTRP has also advanced two other Orphan Disease programs using Bryostatin. We are working with the Ichan School of Medicine at Mt. Sinai Hospital in New York to determine the efficacy of Bryostatin for the treatment of Niemann Pick Disease, Type C. In addition, we are also working with the FRAXA Research Foundation to help find a treatment for Fragile X Syndrome using Bryostatin . NTRP licensed the use of Bryostatin for the treatment of Alzheimers Disease as well as other neurodegenerative diseases from the Blanchette Rockefeller Neuroscience Institute BRNI . To date NTRP has successfully completed a first Phase study in moderate Alzheimers patients. We are now conducting a second Phase study. NTRP has also teamed up with Stanford University to find the next generation Bryostatin Bryologs. lt /p gt
Quote | Neurotrope Inc. (NASDAQ:NTRP)
Last: | $2.97 |
---|---|
Change Percent: | -3.85% |
Open: | $2.97 |
Close: | $2.97 |
High: | $2.97 |
Low: | $2.97 |
Volume: | 610 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Neurotrope Inc. (NASDAQ:NTRP)
2024-04-08 17:43:47 ET More on Sigma Additive Solutions Financial information for Sigma Additive Solutions Read the full article on Seeking Alpha For further details see: NextTrip files to sell common stock, warrants
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communicat...
Message Board Posts | Neurotrope Inc. (NASDAQ:NTRP)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $NTRP News Article - 5 Penny Stocks Gaining Momentum This Week; 1 Up Over 150% | whytestocks | investorshangout | 01/22/2020 3:25:42 PM |
whytestocks: $NTRP News Article - Neurotrope Announces Review of Strategic Alternatives to Maximize | whytestocks | investorshangout | 10/08/2019 1:20:41 PM |
whytestocks: $NTRP News Article - Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chi | whytestocks | investorshangout | 04/01/2019 3:50:41 PM |
whytestocks: $NTRP News Article - Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzh | whytestocks | investorshangout | 03/21/2019 2:05:40 PM |
whytestocks: $NTRP News Article - Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of B | whytestocks | investorshangout | 03/13/2019 7:50:40 PM |
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communicat...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...